Risk-Based Cleaning Validation: Emerging Best Practices for Multi-Product Facilities

Cleaning validation is a critical component of Good Manufacturing Practice (GMP), ensuring that residues from previous products, cleaning agents, and contaminants do not compromise product quality or patient safety. In multi-product facilities, the stakes are even higher. Traditional approaches often rely on fixed limits and exhaustive testing, but regulators and industry leaders are now advocating for risk-based strategies that optimise resources without sacrificing compliance. This blog explores emerging best practices for risk-based cleaning validation, regulatory expectations, and practical implementation tips.

Why Cleaning Validation Matters

In pharmaceutical manufacturing, inadequate cleaning can lead to cross-contamination, product recalls, and regulatory action. Multi-product facilities face unique challenges:

• Diverse product portfolios with varying potency and toxicity.
• Complex equipment trains shared across multiple products.
• Increased pressure to minimise downtime and maximise efficiency.

Cleaning validation provides documented evidence that cleaning processes consistently meet predefined acceptance criteria, safeguarding both patients and manufacturers.

The Shift to Risk-Based Approaches

Traditional cleaning validation often applies uniform limits and testing frequencies, regardless of product risk. This can result in unnecessary testing and resource strain. A risk-based approach tailors validation efforts based on scientific assessment of factors such as:

• Product potency and toxicity.
• Equipment design and cleanability.
• Residue solubility and cleaning agent effectiveness.
• Historical performance data.

By focusing on higher-risk scenarios, manufacturers can allocate resources more effectively while maintaining compliance.

Regulatory Expectations

Global regulators support risk-based strategies, provided they are scientifically justified and documented. Key references include:

• PIC/S Recommendations on Validation Master Plan Installation and Operational Qualification Non-Sterile Process Validation Cleaning Validation
• EMA Health-Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities
• FDA Guidance: Validation of Cleaning Processes
• ICH Q9 on Quality Risk Management

These documents emphasise that risk assessments must be robust, transparent, and integrated into the overall validation lifecycle.

Best Practices for Risk-Based Cleaning Validation

• Conduct Comprehensive Risk Assessments: Evaluate each product-equipment combination for factors like toxicity, solubility, and batch size. Use tools such as Failure Mode and Effects Analysis (FMEA) to prioritise risks.
• Establish Health-Based Exposure Limits (HBELs): Calculate Maximum Allowable Carryover (MACO) using toxicological data. HBELs provide a scientific basis for setting residue limits, replacing arbitrary thresholds.
• Implement Visual Cleanliness as a First Line of Defence: Train operators to recognise residues and document visual inspections. While not sufficient alone, visual checks complement analytical testing.
• Optimise Sampling Strategies: Focus on worst-case locations identified through risk assessment. Swab and rinse sampling should target areas most likely to retain residues.
• Leverage Historical Data: Trend analysis of previous cleaning validation results can identify low-risk scenarios suitable for reduced testing.

Fundamentally it is essential to demonstrate that procedures consistently achieve acceptable cleanliness; include parameters such as cleaning agent concentration, contact time, and temperature in support of your findings and decisions.

Common Pitfalls to Avoid

Cleaning validation is critical for preventing cross-contamination and ensuring product safety, but several common mistakes can undermine its effectiveness:

• Relying on Arbitrary Limits: Using outdated thresholds like “10 ppm” or “1/1000 of the therapeutic dose” without scientific justification is a major compliance risk. Regulators now expect health-based exposure limits (HBEL) derived from toxicological data.
• Ignoring Worst-Case Scenarios: Failing to validate against the most challenging conditions such as the hardest-to-clean equipment or the most potent product can leave gaps in contamination control.
• Inadequate Sampling Strategy: Poorly designed sampling plans, such as insufficient swab locations or neglecting rinse samples, can lead to false assurance of cleanliness.
• Overlooking Equipment Design Issues: Complex equipment with dead legs or inaccessible surfaces often harbours residues. Validation must account for these design challenges.
• Insufficient Documentation: Incomplete protocols, missing rationale for acceptance criteria, or lack of data traceability can result in audit findings—even if cleaning is effective.
• Failure to Integrate Risk Management: Not applying Quality Risk Management (ICH Q9) principles means overlooking factors like product toxicity, solubility, and cleaning agent effectiveness.

Case Study: Applying Health-Based Exposure Limits in Cleaning Validation

Background: A veterinary pharmaceutical manufacturer needed to update its cleaning validation program to comply with EMA’s guideline on health-based exposure limits (HBEL). Historically, the company used fixed limits (10 ppm or 1/1000 dose), which no longer met regulatory expectations.

Challenge: The facility produced multiple products in shared equipment, creating a high risk of cross-contamination. Inspectors expected scientifically justified limits based on toxicological data.

Approach:

• Calculated Permitted Daily Exposure (PDE) for each active substance using toxicological and clinical data.
• Applied Quality Risk Management (ICH Q9) to identify worst-case scenarios for cleaning validation.
• Revised SOPs to incorporate HBEL-derived acceptance criteria and documented the rationale for sampling and limits.
• Trained staff on the new risk-based approach.

Outcome: The updated program demonstrated compliance with EMA expectations, reduced contamination risk, and improved confidence in product safety. The case highlights the shift from arbitrary thresholds to science-driven, patient-focused cleaning validation.
EMA: Application of Health Based Exposure Limits

Future Trends

The landscape of cleaning validation in shared pharmaceutical manufacturing facilities is rapidly evolving, driven by regulatory expectations, technological innovation, and the need for greater efficiency. Risk-based cleaning validation aligns with broader industry moves toward science- and risk-based approaches, as seen in ICH Q12 and continuous manufacturing. Digital tools and automation will further enhance risk assessments and data trending, enabling real-time decision-making.

Several key trends are shaping the future of this critical GMP discipline.

Science- and Risk-Based Approaches

Regulators and industry leaders are moving away from one-size-fits-all validation strategies. The adoption of health-based exposure limits (HBELs) and risk assessment tools, such as Failure Mode and Effects Analysis (FMEA), enables manufacturers to focus resources on the highest-risk scenarios. This targeted approach not only improves compliance but also reduces unnecessary testing and downtime.

Digitalisation and Automation

The integration of digital tools is transforming cleaning validation. Electronic batch records, automated data capture, and advanced analytics allow for real-time monitoring and trending of cleaning performance. Digital risk assessment platforms streamline documentation and facilitate rapid decision-making, while automation in sampling and analysis reduces human error and increases throughput.

Continuous and Real-Time Monitoring

Emerging technologies, such as in-line sensors and rapid analytical methods, are enabling continuous monitoring of cleaning processes. These innovations support real-time release strategies and provide immediate feedback on cleaning effectiveness, reducing the reliance on end-point testing and manual inspections.

Enhanced Data Integrity and Traceability

With increasing regulatory scrutiny on data integrity, future cleaning validation programs will place greater emphasis on secure, traceable, and auditable records. Cloud-based systems and blockchain technology may play a role in ensuring the authenticity and accessibility of validation data.

Integration with Quality by Design (QbD) and Pharma 4.0

Cleaning validation is becoming an integral part of holistic quality systems, aligned with Quality by Design principles and the broader Pharma 4.0 movement. This integration fosters a culture of continuous improvement, leveraging data and automation to optimise cleaning processes throughout the product lifecycle.

Conclusion

Risk-based cleaning validation offers a smarter, more efficient way to ensure product safety in multi-product facilities. By focusing on science and risk, manufacturers can optimise resources, reduce downtime, and maintain compliance. Ready to transition to a risk-based approach? Contact PharmOut today to start your journey.

PharmOut Services

PharmOut helps manufacturers design and implement risk-based cleaning validation programs that meet global regulatory expectations. Our services include:

• Development of HBELs and MACO calculations.
• Risk assessment workshops and documentation support.
• Validation protocol design and execution.
• Training on cleaning validation principles and regulatory compliance.

Explore our GMP training courses at onlinegmptraining.com for practical insights or contact us via the website or via email for assistance.